Recruiting

NCT Number: NCT07539675

The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis

Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Angle-Closure Glaucoma Eye Diseases Glaucoma Glaucoma, Angle-Closure Ocular Hypertension

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430000, China

Location status: Recruiting

Location contact

Min Ke, doctor

CONTACT

[email protected]

18672395959

About this study

This study investigates the pathogenesis of PACG by conducting multi-omics analyses of aqueous humor, blood and anterior lens capsule samples from PACG patients with and without concomitant zonular abnormalities, aiming to elucidate the etiology of zonular abnormalities and uncover novel mechanisms underlying their involvement in the pathogenesis of glaucoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinically diagnosed with primary angle-closure glaucoma (PACG)
Aged ≥ 50 years, no gender restriction
Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery

Exclusion criteria

Secondary glaucoma
History of previous intraocular surgery
Systemic diseases that can cause abnormal ocular zonules
Other severe ocular diseases
Long-term use of medications affecting connective tissue metabolism

Treatment and study plan

No Additional Experimental Intervention

Other

No Additional Experimental Intervention

Primary outcomes

Concentration of differentially expressed molecules in PACG patients with zonular laxity

Time frame: 2 years

Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.

Study contacts

Contact information is provided by the study sponsor or research team.

Min Ke, doctor

CONTACT

[email protected]

18672395959

Xiaomin Chen, doctor

CONTACT

[email protected]

13657237773

Sponsors and collaborators

Lead sponsor

Zhongnan Hospital

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Apr 20, 2026
Registry last updated: Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting